APA

Sandhöfer N., Metzeler K. H., Rothenberg M., Herold T., Tiedt S., Groiß V., Carlet M., Walter G., Hinrichsen T., Wachter O., Grunert M., Schneider S., Subklewe M., Dufour A., Fröhling S., Klein H., Hiddemann W., Jeremias I. & Spiekermann K. (20150604). Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. : Leukemia.

Chicago

Sandhöfer N, Metzeler K H, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein H-G, Hiddemann W, Jeremias I and Spiekermann K. 20150604. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. : Leukemia.

Harvard

Sandhöfer N., Metzeler K. H., Rothenberg M., Herold T., Tiedt S., Groiß V., Carlet M., Walter G., Hinrichsen T., Wachter O., Grunert M., Schneider S., Subklewe M., Dufour A., Fröhling S., Klein H., Hiddemann W., Jeremias I. and Spiekermann K. (20150604). Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. : Leukemia.

MLA

Sandhöfer N, Metzeler K H, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein H-G, Hiddemann W, Jeremias I and Spiekermann K. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. : Leukemia. 20150604.